ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Histogenics Corporation

Histogenics Corporation (HSGX)

0.162
0.00
(0.00%)
終了 1月22日 6:00AM
0.162
0.00
( 0.00% )
プレマーケット: 9:00AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
0.162
買値
0.164
売値
0.166
出来高
-
0.00 日の範囲 0.00
0.00 52 週間の範囲 0.00
時価総額
前日終値
0.162
始値
-
時刻
最終取引時間
-
財務取引量
-
VWAP
-
平均取引量 (3 か月)
-
発行済株式数
256,502,000
配当利回り
-
PER
-3.05
1 株当たり利益 (EPS)
-0.25
歳入
6.04M
純利益
-63.08M

Histogenics Corporation について

Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is an tissue implant that utilizes various aspects of regenerative medicine platform to tre... Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is an tissue implant that utilizes various aspects of regenerative medicine platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Histogenics operates in two geographic regions: The United States (Massachusetts) and Israel (Tel Aviv). Regenerative medicine technologies encompass a variety of therapeutic approaches, including tissue engineering, cell-based therapies, gene therapy, small molecules and biologics, stem cells and biobanking. 詳細を表示

セクター
Biological Pds,ex Diagnstics
業界
Ortho,prosth,surg Appl,suply
ウェブサイト
本社
Wilmington, Delaware, USA
設立
2020

HSGX 最新ニュース

Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan...

Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting

BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen...

Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019

BOSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any...

Histogenics Corporation Announces Intent to Convene and Adjourn Its Special Meeting

BOSTON, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting...

Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel...

BOSTON, Mass. and MALVERN, Penn., April 08, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused...

Jonathan Lieber Joins Danforth Advisors as Managing Director

SOMERVILLE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and...

Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway

WALTHAM, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the...

Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...

Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results

WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to...

Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

HSGX - Frequently Asked Questions (FAQ)

What is the current Histogenics share price?
The current share price of Histogenics is US$ 0.162
How many Histogenics shares are in issue?
Histogenics has 256,502,000 shares in issue
What is the market cap of Histogenics?
The market capitalisation of Histogenics is USD 41.55M
What is the 1 year trading range for Histogenics share price?
Histogenics has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Histogenics?
The price to earnings ratio of Histogenics is -3.05
What is the cash to sales ratio of Histogenics?
The cash to sales ratio of Histogenics is 31.91
What is the reporting currency for Histogenics?
Histogenics reports financial results in USD
What is the latest annual turnover for Histogenics?
The latest annual turnover of Histogenics is USD 6.04M
What is the latest annual profit for Histogenics?
The latest annual profit of Histogenics is USD -63.08M
What is the registered address of Histogenics?
The registered address for Histogenics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Histogenics website address?
The website address for Histogenics is ocugen.com
Which industry sector does Histogenics operate in?
Histogenics operates in the ORTHO,PROSTH,SURG APPL,SUPLY sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
CDIOCardio Diagnostics Holdings Inc
US$ 0.9765
(60.61%)
1.8M
NEHCNew Era Helium Inc
US$ 4.32
(57.66%)
472.74k
ASSTAsset Entities Inc
US$ 1.17
(30.00%)
940k
NFXLDirexion Daily NFLX Bull 2X Shares
US$ 45.24
(28.27%)
4.36k
PLRXPliant Therapeutics Inc
US$ 13.89
(25.47%)
1
STFSStar Fashion Culture Holdings Ltd
US$ 10.50
(-22.28%)
2.34k
TMCITreace Medical Concepts Inc
US$ 7.23
(-22.01%)
6
ELVNEnliven Therapeutics Inc
US$ 17.21
(-21.77%)
1
XENEXenon Pharmaceuticals Inc
US$ 31.51
(-19.16%)
4
LSTALisata Therapeutics Inc
US$ 3.18
(-18.46%)
1
RIMEAlgorhythm Holdings Inc
US$ 0.0386
(11.56%)
2.27M
CDIOCardio Diagnostics Holdings Inc
US$ 0.9765
(60.61%)
1.8M
ASSTAsset Entities Inc
US$ 1.17
(30.00%)
940k
GCTKGlucoTrack Inc
US$ 0.1199
(-4.08%)
797k
SHViShares Short Treasury Bond ETF
US$ 110.365
(0.01%)
697.39k

最近閲覧した銘柄

Delayed Upgrade Clock